行情

VBLT

VBLT

VASCULAR
NASDAQ

实时行情|Nasdaq Last Sale

1.480
+0.051
+3.58%
休市 16:00 01/24 EST
开盘
1.450
昨收
1.429
最高
1.480
最低
1.425
成交量
19.84万
成交额
--
52周最高
1.900
52周最低
0.9300
市值
5,310.41万
市盈率(TTM)
-2.9594
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

VBLT 新闻

  • We're Hopeful That Vascular Biogenics (NASDAQ:VBLT) Will Use Its Cash Wisely
  • Simply Wall St..5天前
  • VBL Therapeutics Announces Publication of Phase 2 and Phase 3 Data of VB-111 in Recurrent Glioblastoma Supporting Continued Development in Investigator-Sponsored Study
  • GlobeNewswire.01/08 13:00
  • UPDATE 2-Mexico's Televisa wins injunction on part of Disney-Fox deal; merger unaffected
  • Reuters.2019/12/06 03:03
  • UPDATE 1-Televisa wins injunction over Disney purchase of Fox assets in Mexico
  • Reuters.2019/12/05 20:32

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

VBLT 简况

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.
展开

Webull提供Vascular Biogenics Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。